Home Neural Analytics Inc.

Neural Analytics Inc.

Neural Analytics, Inc. Announces the First Site Initiation and First Subject Enrollment into the CODEX Study, Utilizing Autonomous Robotic Transcranial Doppler Technology

3/18/19: “There is a growing interest in the diagnostic potential of measuring the dynamic changes of cerebral blood flow in different neurological conditions. Participating in the CODEX Study using the Lucid Robotic System to offer an autonomous measurement of cerebral blood flow velocities has been exciting. We look forward to advancing the field and expanding the clinical relevance of non-invasive measurement of cerebral blood flow in neurological conditions.” - Dr. Ifeanyi Iwuchukwu, MD, assistant professor of Neurocritical Care and Stroke at The Ochsner Clinical Foundation

Neural Analytics, Inc. Receives FDA Clearance for its Robotic Ultrasound System

5/30/18: “Progress in treating neurological disorders has lagged due to a lack of available low-cost and objective patient diagnostic information. This has resulted in misdiagnosis, treatment delays and additional healthcare expenditures for patients suffering neurological disease,” said Robert Hamilton, Ph.D., Co-Founder and Chief Scientific Officer of Neural Analytics.

Neural Analytics, Inc. Raises $15 Million in Series B Financing

1/8/18: Neural Analytics, Inc., a medical device company developing and commercializing technology to measure, diagnose, and track brain health, today announced that it has raised $15 million in Series B financing led by Alpha Edison.

Neural Analytics Announces Data that Demonstrates its Portable Transcranial Doppler Technology Can Accurately Measure Early Strokes Data Presented at 10th Society of Vascular and...

11/13/17: Neural Analytics, Inc., a medical device company developing and commercializing technology to measure, diagnose and track brain health, today announced the results from the first phase of the EXPEDITE (Expedite a NeXt Generation PortablE Diagnostic Platform for Determination and Immediate Triage of Emergency Large Vessel Stroke) program, which (under IRB approved investigation) demonstrates the company’s advanced Transcranial Doppler (TCD) technology platform was accurate with over 94 percent area under the curve (AUC) for early measurement of acute ischemic stroke (AIS) due to large vessel occlusion (LVO). The data was presented at the 10th annual Society of Vascular and Interventional Neurology (SVIN) meeting in Boston, MA.

Neural Analytics Enrolls First Patient in Clinical Study to Evaluate Transcranial Doppler Analytical Platform for Monitoring of Mild Traumatic Brain Injury

HOME Neural Analytics Inc., a medical device company developing and commercializing technology to measure, diagnose and track brain health, today announced the...

Neural Analytics Launches Latest Software Release for the Lucid System, Its Portable Brain Monitoring Information Platform

Home Neural Analytics Inc., a medical device company developing and commercializing technology to measure, diagnose and track brain health, today announced the latest...

New Office in Europe for Neural Analytics

Neural Analytics Inc., a medical device company developing and commercializing technology to measure, diagnose and track brain health, today announced the opening of its new European office based in Hamburg, Germany.

Must Read

New Study Validates Rigorous Safety Measures Needed To Reduce Mercury Exposure During Dental Amalgam Filling Removal

"For decades, our non-profit organization has been concerned about this issue and collected research about amalgam fillings, all of which contain approximately 50% mercury, a known neurotoxin," explains IAOMT President Michael Rehme, DDS, NMD.  "Based on this science, we have strongly recommended that safety measures be enacted for dental procedures involving these silver-colored fillings, and we have also intensely advocated for the end of dental amalgam usage."